Novartis/Sandoz make US history with 1st biosimilar approval
Novartis and its Sandoz subsidiary have made US history, with Zarxio (filgrastim-sndz) – their version of Amgen's Neupogen – becoming the first biosimilar to be approved in the US1-3.
Novartis and its Sandoz subsidiary have made US history, with Zarxio (filgrastim-sndz) – their version of Amgen's Neupogen – becoming the first biosimilar to be approved in the US1-3.